Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
December 29, 2021updated 07 Jan 2022 6:26am

Coronavirus company news summary – Kiniksa’s therapy fails to meet primary goal in Covid-19 trial – UAE grants approval to Sinopharm’s Covid-19 booster

Kiniksa Pharmaceuticals has reported that the Phase III segment of Phase II/III trial analysing mavrilimumab in Covid-19-linked acute respiratory syndrome (ARDS) failed to meet the primary efficacy goal. An experimental fully human monoclonal antibody, mavrilimumab acts on the granulocyte macrophage-colony stimulating factor receptor alpha (GM-CSFRα). The proportion of subjects alive and mechanical ventilation free at day 29 was the primary efficacy goal. The trial analysed the safety and efficacy of the therapy to treat adult Covid-19 patients with hypoxia and severe pneumonia/hyper inflammation in the hospital setting.

The United Arab Emirates (UAE) has granted emergency use authorization to Sinopharm’s protein-based Covid-19 vaccine as a booster dose. The shot will be made available in the region from January next year, Reuters quoted the UAE health ministry as saying. The approval is based on a trial in the UAE that enrolled people who received two doses of the vaccine. In the UAE, the vaccine will be manufactured and supplied by a joint venture between Group 42 and Sinopharm unit China National Biotec Group.

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU